ABSTRACT
BACKGROUND: Opioid overprescribing is a major contributor to the opioid crisis. The lack of procedure-specific guidelines contributes to the vast differences in prescribing practices. OBJECTIVE: To create opioid-prescribing consensus guidelines for common dermatologic procedures. METHODS: We used a 4-step modified Delphi method to conduct a systematic discussion among a panel of dermatologists in the fields of general dermatology, dermatologic surgery, and cosmetics/phlebology to develop opioid prescribing guidelines for some of the most common dermatologic procedural scenarios. Guidelines were developed for opioid-naive patients undergoing routine procedures. Opioid tablets were defined as oxycodone 5-mg oral equivalents. RESULTS: Postoperative pain after most uncomplicated procedures (76%) can be adequately managed with acetaminophen and/or ibuprofen. Group consensus identified no specific dermatologic scenario that routinely requires more than 15 oxycodone 5-mg oral equivalents to manage postoperative pain. Group consensus found that 23% of the procedural scenarios routinely require 1 to 10 opioid tablets, and only 1 routinely requires 1 to 15 opioid tablets. LIMITATIONS: These recommendations are based on expert consensus in lieu of quality evidence-based outcomes research. These recommendations must be individualized to accommodate patients' comorbidities. CONCLUSIONS: Procedure-specific opioid prescribing guidelines may serve as a foundation to produce effective and responsible postoperative pain management strategies after dermatologic interventions.
Subject(s)
Analgesics, Opioid/therapeutic use , Dermatology , Drug Prescriptions/standards , Pain, Postoperative/drug therapy , Practice Patterns, Physicians' , Dermatologic Surgical Procedures , Female , Humans , Male , Practice Guidelines as TopicABSTRACT
BACKGROUND: Atypical fibroxanthoma (AFX) and undifferentiated pleomorphic sarcoma (UPS) are uncommon, spindle cell cutaneous malignancies. Solid organ transplant recipients (SOTRs) are immunosuppressed and therefore have a higher incidence of cutaneous malignancies. OBJECTIVE: We describe the clinical spectrum of AFX and a more-aggressive, deeper variant, UPS, in SOTRs. MATERIALS AND METHODS: A retrospective chart review of AFX and UPS in SOTRs was implemented. Cases from Vanderbilt University, Emory University, Mayo Clinic-Jacksonville, and University of Rochester were included. A literature search included previously published cases. RESULTS: The average age of SOTRs at time of tumor presentation was younger than typically seen in immunocompetent patients for AFX. Rates of local recurrences and metastases were higher in the SOTRs than is noted in the immunocompetent literature. Rates of recurrence were higher in those treated with excision than in those treated with Mohs micrographic surgery (MMS). CONCLUSION: AFX and UPS may have a greater risk for recurrence, metastases, and mortality in SOTRs, in whom early treatment with MMS may demonstrate certain advantages in terms of minimizing risk of recurrence and metastasis. UPS and recurrent tumors should be staged appropriately and may respond to adjuvant radiation therapy and reduction of immunosuppression. Immunohistochemical evaluation is recommended to exclude other spindle cell tumors.
Subject(s)
Heart Transplantation/immunology , Histiocytoma, Benign Fibrous/etiology , Histiocytoma, Malignant Fibrous/etiology , Immunosuppression Therapy/adverse effects , Kidney Transplantation/immunology , Liver Transplantation/immunology , Skin Neoplasms/etiology , Aged , Aged, 80 and over , Histiocytoma, Benign Fibrous/immunology , Histiocytoma, Benign Fibrous/secondary , Histiocytoma, Benign Fibrous/therapy , Histiocytoma, Malignant Fibrous/immunology , Histiocytoma, Malignant Fibrous/pathology , Histiocytoma, Malignant Fibrous/secondary , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Skin Neoplasms/therapyABSTRACT
Previously reported cases of acute generalized exanthematous pustulosis secondary to brown recluse spider bite have been questioned due to lack of identification of the spider or because of the concomitant administration of antibiotics. We report a 9-year-old boy who arrived at the emergency department with a confirmed Loxosceles reclusa bite to the neck. On the third day of hospitalization, he developed hundreds of monomorphous, sterile pustules, initially in intertriginous areas. The eruption disseminated and was followed by pinpoint desquamation typical for acute generalized exanthematous pustulosis. During this he also developed late onset Coombs-positive hemolytic anemia and systemic loxoscelism. Sphingomyelinase in Loxosceles venom induces the production of interleukin-8 and granulocyte-macrophage colony-stimulating factor, cytokines involved in the pathogenesis of acute generalized exanthematous pustulosis, providing a mechanism by which Loxosceles reclusa bite may trigger acute generalized exanthematous pustulosis. We suggest that this case adds Loxosceles envenomation to the spectrum of agents that can trigger acute generalized exanthematous pustulosis.
Subject(s)
Acute Generalized Exanthematous Pustulosis/etiology , Anemia, Hemolytic/etiology , Phosphoric Diester Hydrolases/adverse effects , Spider Venoms/adverse effects , Acute Generalized Exanthematous Pustulosis/diagnosis , Anemia, Hemolytic/diagnosis , Blood Transfusion , Child , Coombs Test , Dopamine/therapeutic use , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Heart Failure/etiology , Heart Failure/therapy , Humans , Interleukin-8/biosynthesis , Male , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/therapy , Sphingomyelin Phosphodiesterase/adverse effects , Treatment Outcome , Urobilinogen/urineABSTRACT
BACKGROUND: Superficial leg veins affect millions of people worldwide, and treatment of these vessels is a common dermatologic request. The advance of lasers in recent years has led to numerous laser and light devices intended to treat these superficial vessels. OBJECTIVE AND METHOD: A review of the literature on the laser and light devices available for the treatment of superficial leg vessels with historical and recent trends is presented. RESULTS AND CONCLUSIONS: The appropriate choice of light system to treat telangiectases, venulectases, and reticular veins varies depending on anatomical, physiological, and biological differences in the vessels. Safe and efficacious treatment of superficial leg vessels can be achieved with multiple lasers by taking advantage of the oxyhemoglobin absorption peaks. The authors have indicated no significant interest with commercial supporters.
Subject(s)
Laser Therapy/methods , Leg/blood supply , Skin Diseases, Vascular/surgery , Telangiectasis/surgery , Humans , Lasers, Dye/therapeutic use , Lasers, Semiconductor/therapeutic use , Lasers, Solid-State/therapeutic useSubject(s)
Adenoma, Sweat Gland/immunology , Cyclosporine/adverse effects , Immunosuppressive Agents/adverse effects , Muir-Torre Syndrome/immunology , Neoplasm Recurrence, Local/immunology , Adenoma, Sweat Gland/epidemiology , Comorbidity , Cyclosporine/therapeutic use , Drug Therapy, Combination , Humans , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/surgery , Kidney Transplantation , Male , Middle Aged , Muir-Torre Syndrome/chemically induced , Neoplasm Recurrence, Local/chemically induced , Sirolimus/therapeutic useABSTRACT
BACKGROUND: Telangiectases affect millions of people worldwide, and treatment of these vessels is a common dermatologic request. The advancement of lasers in recent years has led to numerous laser and light devices intended to treat telangiectases. OBJECTIVE AND METHOD: A review of the literature on the laser and light devices available for the treatment of telangiectases with both historical and recent trends is presented. RESULTS: The appropriate choice of light system to treat telangiectases varies depending on anatomical, physiological, and biological differences in the vessels. Safe and efficacious treatment of facial telangiectases can be achieved with the green and yellow light lasers by taking advantage of the oxyhemoglobin absorption peaks. The authors have indicated no significant interest with commercial supporters.